Search by drug, manufacturer, or indication

Displaying 751 - 760 of 1165

Vitrakvi (larotrectinib)

Status:

Negotiations were not pursued

Manufacturer:

Bayer Inc.

Indication:

Neurotrophic Tyrosine Receptor Kinase (NTRK) Locally Advanced or Metastatic Solid Tumours

Last updated December 30, 2019

Lutathera (lutetium 177 dotatate)

Status:

Concluded without agreement

Manufacturer:

Advanced Accelerator Applications

Indication:

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Last updated December 30, 2019

Prevymis (letermovir)

Status:

Concluded with an LOI

Manufacturer:

Merck Canada Inc.

Indication:

Cytomegalovirus infection prophylaxis

Last updated December 18, 2019

Keytruda (pembrolizumab)

Status:

Negotiations were not pursued

Manufacturer:

Merck Canada Inc.

Indication:

Metastatic Urothelial Carcinoma (first line)

Last updated November 29, 2019

Skyrizi (risankizumab)

Status:

Concluded with an LOI

Manufacturer:

AbbVie Corporation

Indication:

Psoriasis, moderate to severe plaque

Last updated November 28, 2019

Cresemba (isavuconazole)

Status:

Concluded with an LOI

Manufacturer:

AVIR Pharma Inc.

Indication:

Invasive aspergillosis and mucormycosis

Last updated November 25, 2019

Mavenclad (cladribine)

Status:

Concluded with an LOI

Manufacturer:

EMD Serono Canada, a division of EMD Inc.

Indication:

Multiple Sclerosis, Relapsing

Last updated November 22, 2019

Dovato (dolutegravir/lamivudine)

Status:

Concluded with an LOI

Manufacturer:

ViiV Healthcare

Indication:

HIV-1 Infection

Last updated November 21, 2019

Soliqua (lixisenatide/insulin glargine)

Status:

Concluded with an LOI

Manufacturer:

Sanofi-Aventis Canada Inc.

Indication:

Diabetes Mellitus, Type 2

Last updated November 21, 2019

Adlyxine (lixisenatide)

Status:

Concluded with an LOI

Manufacturer:

Sanofi-Aventis Canada Inc.

Indication:

Diabetes Mellitus, Type 2

Last updated November 21, 2019